NCT03417882 — Metastatic NSCLC trial site landscape

Public-registry site landscape for NCT03417882, “GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC”, a Metastatic NSCLC study sponsored by BrightPath Biotherapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT03417882 (registry record)
Study title	GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Official title	A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Sponsor	BrightPath Biotherapeutics
Condition(s)	Metastatic NSCLC
Phase	PHASE2
Listed sites	11
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT03417882.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT03417882 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →